ResearcherWashington University in St. LouisNo recent work listed
Koushik K. Das
Matched on ORCID iD 0000-0003-4533-1105; OpenAlex author ID A5039309088. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 45
2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: 2 papers
Papers 8
- High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival. Co-author DOI 10.1038/s41698-023-00455-z↗
- Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad002↗
- mAb Das-1 identifies pancreatic ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia with high accuracy. Co-author DOI 10.1016/j.humpath.2021.01.003↗
- EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer. Co-author DOI 10.1158/1940-6207.capr-21-0161↗
- Comparison of endoscopic ultrasound tissue acquisition methods for genomic analysis of pancreatic cancer. Co-author DOI 10.1111/jgh.14540↗
- Pancreatic Cancer Screening. Co-author DOI 10.1007/s11938-017-0149-8↗
- ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. First author DOI 10.1053/j.gastro.2016.06.005↗
- Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Co-author DOI 10.1101/gad.263327.115↗
Closest collaborators
The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Anil K. Rustgi · 4 shared papers, 2016–2023 · strength 0.33
- Paper Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Ca… DOI 10.1093/oncolo/oyad002↗
- Paper EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cance… DOI 10.1158/1940-6207.capr-21-0161↗
- Paper Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. DOI 10.1101/gad.263327.115↗
- Dayna S. Early · 2 shared papers, 2017–2023 · strength 0.27
- Basil S. Bakir · 3 shared papers, 2016–2023 · strength 0.23
- Paper Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Ca… DOI 10.1093/oncolo/oyad002↗
- Paper Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. DOI 10.1101/gad.263327.115↗
- Paper ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. DOI 10.1053/j.gastro.2016.06.005↗
- Yoko Matsuda · 1 shared paper, 2021 · strength 0.14
- Mari A. Mino-Kenudson · 1 shared paper, 2021 · strength 0.14
- Douglas Adam Rubinson · 1 shared paper, 2023 · strength 0.13
- Srivatsan Raghavan · 1 shared paper, 2023 · strength 0.13
- Thomas Adam Abrams · 1 shared paper, 2023 · strength 0.13
- Lawrence Scott Blaszkowsky · 1 shared paper, 2023 · strength 0.13
- Andrew J. Aguirre · 1 shared paper, 2023 · strength 0.13
- Matthew B.B. Yurgelun · 1 shared paper, 2023 · strength 0.13
- Brian Matthew Wolpin · 1 shared paper, 2023 · strength 0.13
- Kimberly J. Perez · 1 shared paper, 2023 · strength 0.13
- Jason Robert Pitarresi · 1 shared paper, 2023 · strength 0.13
- Colin D. Weekes · 1 shared paper, 2023 · strength 0.13
- James M. Cleary · 1 shared paper, 2023 · strength 0.13
- Wolfram Goessling · 1 shared paper, 2023 · strength 0.13
- William G. Hawkins · 1 shared paper, 2023 · strength 0.12
- Ashiq Masood · 1 shared paper, 2023 · strength 0.12
- Deyali Chatterjee · 1 shared paper, 2023 · strength 0.12
- Gabriel D. Lang · 1 shared paper, 2023 · strength 0.12
- Vladimir M. Kushnir · 1 shared paper, 2023 · strength 0.12
- Erik P. Storrs · 1 shared paper, 2023 · strength 0.12
- Aadel A. Chaudhuri · 1 shared paper, 2023 · strength 0.12
- Hyun Jee Kim · 1 shared paper, 2023 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.